In the West, it was reported that the ovarian cancer risk was higher in the BRCA1 mutation group than in the BRCA2 mutation group, while the prostate cancer risk was higher in the BRCA2 group than in the BRCA1 group. This evidence concerns the gene BRCA2 and prostate cancer.